SILVERMAN, E. (2011). Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum? BioCommunications LLC.
Chicago Style CitationSILVERMAN, ED. Setting the Bar Higher For Off-Label Use of Biologics: Off-label Use of Biologics Is Common As Physicians Strive for Optimal Treatment. Patients Want Whatever Works. Drug Makers Want Expanded Labeling, but Payers Chafe At the Lack of Efficacy Data. Is There an Answer to This Conundrum? BioCommunications LLC, 2011.
Cita MLASILVERMAN, ED. Setting the Bar Higher For Off-Label Use of Biologics: Off-label Use of Biologics Is Common As Physicians Strive for Optimal Treatment. Patients Want Whatever Works. Drug Makers Want Expanded Labeling, but Payers Chafe At the Lack of Efficacy Data. Is There an Answer to This Conundrum? BioCommunications LLC, 2011.